Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Heparin binds to antithrombin III, accelerating its inhibition of thrombin (factor IIa) and factor Xa, leading to anticoagulation.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Prophylaxis and treatment of venous thrombosis and pulmonary embolism,Treatment of atrial fibrillation with embolization,Prevention of clotting in blood transfusions, extracorporeal circulation, and dialysis procedures,Off-label: Treatment of disseminated intravascular coagulation (DIC)
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Continuous IV infusion: Initial bolus 80 units/kg, then 18 units/kg/hour; adjust based on a PTT. Typical infusion rate: 1000-2000 units/hour for adults.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Terminal elimination half-life: 1.5–2 hours (dose-dependent and saturable clearance); prolonged in hepatic/renal impairment and at higher doses.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Primarily metabolized by the liver via desulfation and depolymerization; partially cleared by the reticuloendothelial system.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal: 40% (as unchanged drug and metabolites); hepatic/biliary: minimal (<5%); fecal: negligible.
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Very high: ~95–98% (primarily to antithrombin III, also albumin and other proteins); binding is saturable.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Vd: 0.05–0.1 L/kg; primarily confined to plasma volume (low distribution); minimal extravascular penetration.
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Subcutaneous: 30–35% (due to first-pass clearance and tissue binding); intravenous: 100%.
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
No specific GFR-based dose adjustment required; monitor a PTT closely in renal impairment due to increased bleeding risk.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No established Child-Pugh based guidelines; use with caution and monitor a PTT due to reduced antithrombin III and increased bleeding risk.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
IV: Bolus 75-100 units/kg, then maintenance infusion 20-25 units/kg/hour; adjust to target a PTT.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Lower initial doses recommended (e.g., bolus 50-60 units/kg, infusion 12-15 units/kg/hour) due to altered pharmacokinetics and increased bleeding risk; monitor a PTT closely.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
Heparin-induced thrombocytopenia (HIT) can occur; monitor platelets closely. Risk of bleeding, especially in patients with uncontrolled hypertension or concomitant use of antiplatelet agents.
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
Monitor for signs of bleeding; adjust dose based on a PTT. Discontinue if HIT is confirmed. Use with caution in renal impairment, hepatic disease, or history of gastrointestinal ulcers.
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypersensitivity to heparin or pork products,Active major bleeding,Thrombocytopenia (platelet count <100,000/μL) due to HIT,Uncontrolled severe hypertension
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No specific food interactions with heparin. However, foods high in vitamin K (e.g., leafy greens) may theoretically affect coagulation but are not clinically significant with heparin therapy. Maintain a consistent diet if on concurrent warfarin.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Heparin does not cross the placenta and has not been associated with teratogenicity in any trimester. No increased risk of fetal malformations. Prolonged use may be associated with maternal osteoporosis and hemorrhage, but fetal risks are minimal.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Heparin is not excreted into breast milk due to its high molecular weight and lack of oral bioavailability. Considered compatible with breastfeeding. M/P ratio is not available but expected to be negligible.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
Pregnancy increases plasma volume and renal clearance, potentially requiring higher or more frequent doses to maintain therapeutic anti-Xa levels. Monitor anti-Xa levels and adjust dose accordingly. Consider weight-based dosing. Postpartum, doses may need reduction.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
This formulation contains sodium chloride 0.45% (half-normal saline) and heparin 25,000 units. It is commonly used for continuous IV infusion to maintain catheter patency or for anticoagulation. Verify the concentration before administration; a common error is confusing this with heparin flush solutions. Monitor a PTT closely when used for systemic anticoagulation; the half-normal saline may affect fluid balance in patients with renal impairment or heart failure. Use with caution in patients with heparin-induced thrombocytopenia (HIT).
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
This medication is an anticoagulant that helps prevent blood clots.,You will receive this medication through an intravenous (IV) line.,Report any signs of bleeding, such as unusual bruising, blood in urine or stool, or prolonged bleeding from cuts.,Avoid activities that may cause injury or bleeding while on this medication.,Inform your healthcare provider if you have a history of heparin-induced thrombocytopenia (HIT) or other bleeding disorders.,Do not take aspirin or other NSAIDs (e.g., ibuprofen) unless prescribed by your doctor.,You may need frequent blood tests to monitor your response to the medication.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is a Electrolyte that works by Heparin binds to antithrombin III, accelerating its inhibition of thrombin (factor IIa) and factor Xa, leading to anticoagulation.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is: Continuous IV infusion: Initial bolus 80 units/kg, then 18 units/kg/hour; adjust based on a PTT. Typical infusion rate: 1000-2000 units/hour for adults.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. HEPARIN SODIUM 25,000 UNITS IN SODIUM CHLORIDE 0.45% IN PLASTIC CONTAINER is classified as Category A/B. Heparin does not cross the placenta and has not been associated with teratogenicity in any trimester. No increased risk of fetal malformations. Prolonged use may be associated with. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.